Bacteria play an important role in the pathogenesis of inflammatory bowel disease (IBD), its complications and its symptoms. Antibiotics can decrease tissue invasion and eliminate aggressive bacterial species. They are used in IBD to treat infective complications and for altering bacterial flora, which may result in specific anti-inflammatory effects. In addition, suppression of bacterial metabolic activities or direct effects of antibiotics on intestinal structures and functions may result in symptoms which cannot be differentiated from symptoms caused by inflammation. Although current clinical trials do not fulfill criteria of evidence-based treatment, a few placebo- or standard treatment-controlled studies suggest that metronidazole and ciprofloxacin are effective in Crohn’s colitis and ileocolitis, perianal fistulae and pouchitis. Administration of probiotics, prebiotics and synbiotics can restore a predominance of beneficial species. However, beneficial effects of probiotics in IBD are modest, strain-specific and limited to certain manifestations of disease and duration of use of the probiotic. For probiotics there is reasonable evidence of efficacy in relapse prevention in chronic pouchitis and ulcerative colitis, and suggestive evidence for postoperative prevention in pouchitis. Therapeutic manipulation of the intestinal flora offers considerable promise for treating IBD, but must be supported by large controlled therapeutic trials before widespread clinical acceptance. These agents may become a component of treating IBD in combination with traditional anti-inflammatory and immunosuppressive agents. Probiotic strategies, based on metagenomic or metabonomic analyses, and new classes of probiotics might play an important role in the future management of IBD.

Keywords:
Probiotics, Antibiotics, Ulcerative colitis, Crohn’s disease, Pouchitis, Diarrhea
1.
Preidis GA, Versalovic J: Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterolgoy enters the metagenomics era. Gastroenterology 2009;136:2015–2031.
2.
MacDonald TT, Monteleone G: Immunity, inflammation and allergy in the gut. Science 2005;307:1920–1925.
3.
Sartor RB: Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004;126:1620–1633.
4.
Sheil B, Shanahan F, O’Mahony L: Probiotic effects on inflammatory bowel disease. J Nutr 2007;137:819S–824S.
5.
Hammer HF, Fine KD, Santa Ana CA, Porter JL, Schiller LR, Fordtran JS: Carbohydrate malabsorption: its measurement and its contribution to diarrhea. J Clin Invest 1990;86:1936–1944.
6.
Hammer HF: Colonic gas absorption – quantification of its effect on gas accumulation caused by bacterial fermentation of carbohydrates. Gut 1993;34:818–822.
7.
Fruhwald S, Herk E, Schöll G, Shabazian A, Hammer HF, Metzler H, Holzer P: Endotoxin pretreatment modifies peristalsis and attenuates the antipropulsive action of adrenoceptor agonists in the guinea-pig small intestine. Neurogastroenterol Motil 2004;16:213–222.
8.
Fritz E, Hammer HF, Lipp RW, Högenauer C, Stauber RW, Hammer J: Effect of lactulose and polyethylene glycol on colonic transit. Aliment Pharmacol Ther 2005;21:259–268.
9.
Högenauer C, Hammer HF, Krejs GJ, Reisinger EC: Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis 1998;27:702–710.
10.
Butterworth AD, Thomas AG, Akobeng AK: Probiotics for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2008;3:CD006634.
11.
Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall FJ: Probiotics for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2006;4:CD004826.
12.
Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, Danese S, D’Hoore A, Gassull M, Gomollón F, Hommes DW, Michetti P, O’Morain C, Öresland T, Windsor A, Stange EF, Travis SPL, European Crohn’s and Colitis Organisation (ECCO): The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 2010;4:28–62.
13.
Mallon PT, McKay D, Kirk SJ, Gardiner K: Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;4:CD005573.
14.
Travis SPL, Stange EF, Lémann M, Øresland T, Bemelman MA, Chowers Y, Colombel JF, D’Haens G, Ghosh S, Marteau P, Kruis W, Mortensen NJMcC, Penninckx F, Gassull M, European Crohn’s and Colitis Organisation (ECCO) European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008;2:24–62.
15.
Holubar SD, Cima RR, Sandborn WJ, Pardi DS: Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 2010;6:CD001176.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.